| Personalized medicine: recent progress in cancer therapy V Gambardella, N Tarazona, JM Cejalvo, P Lombardi, M Huerta, ... Cancers 12 (4), 1009, 2020 | 159 | 2020 |
| Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes F Loupakis, I Depetris, P Biason, R Intini, AA Prete, F Leone, P Lombardi, ... The oncologist 25 (6), 481-487, 2020 | 98 | 2020 |
| Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 L Marandino, A La Salvia, C Sonetto, E De Luca, D Pignataro, C Zichi, ... Annals of oncology 29 (12), 2288-2295, 2018 | 82 | 2018 |
| The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer M Salati, R Filippi, C Vivaldi, F Caputo, F Leone, F Salani, K Cerma, ... Liver International 40 (3), 704-711, 2020 | 47 | 2020 |
| Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018 ML Reale, E De Luca, P Lombardi, L Marandino, C Zichi, D Pignataro, ... Lung Cancer 139, 47-54, 2020 | 39 | 2020 |
| Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor A Fadda, D Gentilini, L Moi, L Barault, VP Leoni, P Sulas, L Zorcolo, ... International journal of cancer 143 (4), 907-920, 2018 | 39 | 2018 |
| New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis P Lombardi, M Filetti, R Falcone, R Di Bidino, R Iacovelli, C Ciccarese, ... Cancer Treatment Reviews 106, 102377, 2022 | 25 | 2022 |
| Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, STROBE-compliant, single-center study comparing chemotherapy alone and … M Basso, V Dadduzio, F Ardito, P Lombardi, A Strippoli, M Vellone, ... Medicine 95 (20), e3722, 2016 | 24 | 2016 |
| Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018 P Lombardi, L Marandino, E De Luca, C Zichi, ML Reale, D Pignataro, ... Critical reviews in oncology/hematology 146, 102877, 2020 | 20 | 2020 |
| Evaluation of second-line anti-VEGF after first-line Anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: the Multicenter “SLAVE” Study A Parisi, A Cortellini, K Cannita, O Venditti, F Camarda, MA Calegari, ... Cancers 12 (5), 1259, 2020 | 19 | 2020 |
| Oncologic drugs approval in Europe for solid tumors: overview of the last 6 years R Falcone, P Lombardi, M Filetti, S Duranti, A Pietragalla, A Fabi, ... Cancers 14 (4), 889, 2022 | 16 | 2022 |
| Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study V Gambardella, P Lombardi, JA Carbonell-Asins, N Tarazona, JM Cejalvo, ... British Journal of Cancer 125 (9), 1261-1269, 2021 | 16 | 2021 |
| Quality-Of-Life assessment and reporting in prostate cancer: systematic review of phase 3 trials testing anticancer drugs published between 2012 and 2018 L Marandino, E De Luca, C Zichi, P Lombardi, ML Reale, D Pignataro, ... Clinical Genitourinary Cancer 17 (5), 332-347. e2, 2019 | 16 | 2019 |
| Overview of Trop-2 in cancer: from pre-clinical studies to future directions in clinical settings P Lombardi, M Filetti, R Falcone, V Altamura, F Paroni Sterbini, E Bria, ... Cancers 15 (6), 1744, 2023 | 15 | 2023 |
| Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory metastatic colorectal cancer (mCRC) patients: a multi-institution real life clinical data P Vitale, N Zanaletti, V Famiglietti, V De Falco, A Cervantes, S Rosello, ... Clinical Colorectal Cancer 20 (3), 227-235, 2021 | 15 | 2021 |
| Emerging molecular target antagonists for the treatment of biliary tract cancer P Lombardi, D Marino, E Fenocchio, G Chilà, M Aglietta, F Leone Expert Opinion on Emerging Drugs 23 (1), 63-75, 2018 | 15 | 2018 |
| Validated nomogram predicting 6-month survival in pancreatic cancer patients receiving first-line 5-fluorouracil, oxaliplatin, and irinotecan L Fornaro, F Leone, A Vienot, A Casadei-Gardini, C Vivaldi, A Lièvre, ... Clinical colorectal cancer 18 (4), e394-e401, 2019 | 14 | 2019 |
| Breast cancer drug approvals issued by EMA: A review of clinical trials S Duranti, A Fabi, M Filetti, R Falcone, P Lombardi, G Daniele, ... Cancers 13 (20), 5198, 2021 | 13 | 2021 |
| Is there a standard adjuvant therapy for resected pancreatic cancer? E Fenocchio, R Filippi, P Lombardi, V Quarà, M Milanesio, G Aimar, ... Cancers 11 (10), 2019 | 13 | 2019 |
| Improvement of metastatic colorectal cancer patient survival: single institution experience E Fenocchio, F Colombi, MG Calella, R Filippi, I Depetris, G Chilà, ... Cancers 11 (3), 369, 2019 | 9 | 2019 |
